Cannabis Law Now Podcast: THC Infused Beverages: Cantrip's Journey Through the Hemp-Derived Looking Glass
A Look at Non-Cannabis Derived CBD Products
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 121: Kevin Sills, CEO, Asterra Labs
[Webinar] Minor Cannabinoids & Trending Topics in Hemp
A Look Inside the Expanding Cannabis-Infused Beverage Market With the CEO of Hillview, Producer of Hemp-Infused Seltzer Brand Kaló
Podcast: Federal and State Cannabis Rules Are Moving in Different Directions - Diagnosing Health Care
Cannabis Counsel Cast: What Cannabis Companies Need to Know About California’s Prop. 65 (Even if They Aren’t in California)
From FDA to USDA – the Alphabet Soup of Regulatory Agencies and How the Government Has Permitted Some Flexibility During the Pandemic
More CBD Certainty: Clearing Confusion over Hemp in New York State
Holding Pattern: Cannabis Industry Waits for FDA Regulatory Rulemaking - Diagnosing Health Care Podcast
Canna We Talk Cannabis? Not So Patently Obvious: Patent Infringement in the Cannabis Industry
Canna We Talk Cannabis? Emerging Topics in Cannabis Law
Podcast: Non-binding Guidance: FDA’s Regulation of Products Containing CBD
Health Canada recently announced that it is exploring a regulatory pathway that would allow products containing cannabidiol (“CBD”) to be purchased without a prescription. Under the current regulatory scheme, all health...more
On Jan. 23, the Food and Drug Administration (FDA) finalized industry guidance for clinical research using cannabis and cannabis-derived compounds, Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical...more
On May 4, 2022, the U.S. Food and Drug Administration (FDA) issued warning letters to five companies for selling products labeled as containing delta-8 tetrahydrocannabinol (delta-8 THC) in ways that violate the Federal Food,...more
Examining attorneys at the U.S. Patent and Trademark Office (USPTO) are citing a recent 2020 decision by the Trademark Trial and Appeal Board (TTAB) to support the position that trademarks for many products (particularly...more
Arnall Golden Gregory LLP's Food and Drug Newsletter is a monthly update of legal and regulatory issues that affect the FDA-regulated community and highlights articles from members of AGG outside the Food and Drug practice....more
This is our third year-end post for 2019 related to the Food and Drug Administration (FDA), focusing on the agency’s activities in the widely divergent area of “consumer products.” In taking a wide-lens view of the past year,...more
Food/Dietary Supplements - FDA Acting Commissioner Remarks on Smarter Public Food Safety – Dr. Sharpless stated, “I have been [a] strong proponent of leveraging new and emerging technologies and of developing novel analytical...more
Legislation - Biologics: Senate Health Committee Passes Bipartisan Legislation to Lower Health Care Costs - During the last week of June, the Senate Health, Education, Labor, and Pensions (HELP) Committee approved...more
Sharpless Begins as FDA Acting Commissioner – On April 5, Norman E. “Ned” Sharpless, M.D., became the acting commissioner of the FDA. Previously he was the director of the National Cancer Institute....more
Cannabis/Marijuana- South Dakota Attorney General Issues Clarifying Statement on Legality of Industrial Hemp and Cannabidiol Oil- South Dakota AG Jason Ravnsborg issued a clarifying statement regarding the legality of...more
Food/Dietary Supplements - FDA Releases Imported Food Safety Strategy – The FDA announced its imported food safety strategy. ...more